SLRX - Salarius Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Houston,
United States
Type: Equity
SLRX price evolution
SLRX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.9 | $7.58 | $11.54 | $9.27 |
| Short term investments | ||||
| Net receivables | $0.13 | $0.13 | ||
| Inventory | ||||
| Total current assets | $6.52 | $8.32 | $11.96 | $9.94 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.07 | $0.08 | $0.1 | $0.11 |
| Total investments | ||||
| Total assets | $6.59 | $8.4 | $12.06 | $10.06 |
| Current liabilities | ||||
| Accounts payable | $0.6 | $1.09 | $2.29 | $3.51 |
| Deferred revenue | ||||
| Short long term debt | $0.29 | $0.46 | ||
| Total current liabilities | $1.3 | $2.32 | $3.64 | $4.5 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.29 | $0.46 | ||
| Total liabilities | $1.3 | $2.32 | $3.64 | $4.5 |
| Shareholders' equity | ||||
| Retained earnings | -$76.35 | -$75.47 | -$73.02 | -$69.15 |
| Other shareholder equity | ||||
| Total shareholder equity | $5.29 | $6.08 | $8.41 | $5.56 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.9 | $12.11 | $29.21 | $11.12 |
| Short term investments | ||||
| Net receivables | $1.61 | $1.61 | $3.86 | |
| Inventory | ||||
| Total current assets | $6.52 | $14.52 | $30.16 | $15.8 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $0.02 | ||
| Goodwill & intangible assets | $8.87 | $8.87 | ||
| Total noncurrent assets | $0.07 | $0.13 | $10.67 | $9.14 |
| Total investments | ||||
| Total assets | $6.59 | $14.65 | $40.83 | $24.93 |
| Current liabilities | ||||
| Accounts payable | $0.6 | $2.86 | $1.54 | $1.85 |
| Deferred revenue | ||||
| Short long term debt | $0.29 | $0.48 | ||
| Total current liabilities | $1.3 | $4.27 | $2.11 | $2.77 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.29 | $0.48 | ||
| Total liabilities | $1.3 | $4.27 | $2.11 | $2.77 |
| Shareholders' equity | ||||
| Retained earnings | -$76.35 | -$63.81 | -$32.2 | -$19.43 |
| Other shareholder equity | ||||
| Total shareholder equity | $5.29 | $10.38 | $38.72 | $22.16 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.06 | $1.04 | $2.35 | $3.73 |
| Selling, general & administrative | $0.91 | $1.5 | $1.62 | $1.7 |
| Total operating expenses | $0.97 | $2.53 | $3.97 | $5.42 |
| Operating income | -$0.97 | -$2.53 | -$3.97 | -$5.42 |
| Income from continuing operations | ||||
| EBIT | -$0.88 | -$2.44 | -$3.88 | -$5.34 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$0.88 | -$2.44 | -$3.88 | -$5.34 |
| Income (for common shares) | -$0.88 | -$2.44 | -$3.88 | -$5.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.84 | $5.23 | ||
| Cost of revenue | ||||
| Gross Profit | $1.84 | $5.23 | ||
| Operating activities | ||||
| Research & development | $7.17 | $15.84 | $8.55 | $6.91 |
| Selling, general & administrative | $5.72 | $7.14 | $6.1 | $6.11 |
| Total operating expenses | $12.89 | $31.84 | $14.65 | $13.02 |
| Operating income | -$12.89 | -$31.84 | -$12.81 | -$7.79 |
| Income from continuing operations | ||||
| EBIT | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Income tax expense | ||||
| Interest expense | $0 | |||
| Net income | ||||
| Net income | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Income (for common shares) | -$12.54 | -$31.61 | -$12.77 | -$7.75 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$0.88 | -$2.44 | -$3.88 | -$5.34 |
| Operating activities | ||||
| Depreciation | $0 | $0.01 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.09 | $0.11 | $0.12 | $0.2 |
| Total cash flows from operations | -$1.51 | -$3.75 | -$4.42 | -$3.17 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0 | -$0.1 | $6.68 | $0.34 |
| Net borrowings | -$0.17 | -$0.11 | ||
| Total cash flows from financing | -$0.17 | -$0.21 | $6.68 | $0.34 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.68 | -$3.96 | $2.27 | -$2.83 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$1.5 | |||
| Stock-based compensation | $0.52 | $0.8 | $0.56 | $0.32 |
| Total cash flows from operations | -$12.85 | -$17.6 | -$10.2 | -$10.31 |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$1.5 | -$0 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.92 | $1.99 | $27.29 | $14.8 |
| Net borrowings | -$0.28 | -$0.48 | -$0.97 | |
| Total cash flows from financing | $6.64 | $1.99 | $28.3 | $17.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.21 | -$17.11 | $18.1 | $7.38 |
News
Fundamentals
| Market cap | $2.00M |
|---|---|
| Enterprise value | -$3.61M |
| Shares outstanding | 3.94M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$12.53M |
| EBIT | -$12.54M |
| Net Income | -$12.54M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.16 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | 0.29 |
| EV/EBIT | 0.29 |
| P/S ratio | N/A |
| P/B ratio | 0.38 |
| Book/Share | 1.34 |
| Cash/Share | 1.50 |
| EPS | -$3.18 |
|---|---|
| ROA | -135.23% |
| ROE | -197.96% |
| Debt/Equity | 0.25 |
|---|---|
| Net debt/EBITDA | 0.37 |
| Current ratio | 5.02 |
| Quick ratio | 5.02 |